Quizartinib vs XY0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline

Quizartinib

Marketed by Daiichi Sankyo and partners

Approved in Acute Myeloid Leukemiasmall molecule
Reliable signal

NCT02668653 · Phase 3 · completed

The trial randomized 539 participants to quizartinib plus chemotherapy or placebo plus chemotherapy, with participants, investigators, and outcome assessors masked. Its hard primary endpoint, overall survival, was met in favor of quizartinib, with a statistically significant hazard ratio of 0.776 (p=0.0324).

Next expected readout: May 2027 · NCT03793478 (registry estimate)

Reported efficacy

Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) (met)

Result source: NCT02668653

XY0206

Developed by Shijiazhuang Yiling Pharmaceutical Co. Ltd

Phase 3 in Acute Myeloid Leukemiasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: July 2027 · NCT05876832 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointQuizartinibXY0206
OS, median31.9 vs 15.1+16.8 vs placebon 268NCT02668653
8 other results
—Trial running · NCT05876832
Complete remission2.6%b60 mg · wk 156 · n 38NCT01565668
1 other result
  • 5.3% 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
—Trial running · NCT05876832
Event-free survival, median0.0 vs 0.7−0.7 vs placebon 268NCT02668653
5 other results
  • 1.4 vs 0.8 wk 195 · n 245 · Phase 3 · secondary NCT02039726
  • 3.2 60 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.8 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.9 30 mg/day · n 29 · Phase 2 · secondary NCT02984995
  • 0.0 20 mg/day · n 3 · Phase 2 · secondary NCT02984995
—Trial running · NCT05876832
Duration of response, median3.6bn 83NCT00989261
3 other results
—Trial running · NCT05876832

OS, median

Quizartinib
31.9 vs 15.1+16.8 vs placebon 268NCT02668653
8 other results
XY0206
—Trial running · NCT05876832

Complete remission

Quizartinib
2.6%b60 mg · wk 156 · n 38NCT01565668
1 other result
  • 5.3% 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
XY0206
—Trial running · NCT05876832

Event-free survival, median

Quizartinib
0.0 vs 0.7−0.7 vs placebon 268NCT02668653
5 other results
  • 1.4 vs 0.8 wk 195 · n 245 · Phase 3 · secondary NCT02039726
  • 3.2 60 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.8 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.9 30 mg/day · n 29 · Phase 2 · secondary NCT02984995
  • 0.0 20 mg/day · n 3 · Phase 2 · secondary NCT02984995
XY0206
—Trial running · NCT05876832

Duration of response, median

Quizartinib
3.6bn 83NCT00989261
3 other results
XY0206
—Trial running · NCT05876832
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

XY0206: no structured comparison results are available for Acute Myeloid Leukemia.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Quizartinib: 4 of 4 rows · XY0206: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricQuizartinib
Dropout rate
79.1%a
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
18.4%
NCT02039726 · Phase 3 · registry result, not featured evidence
73.5%30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
—20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
100%20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone60 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
9.6%Cohort 1; ≥60 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
12.5%Cohort 2; ≥18 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
0%Phase 1 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
66.7%40 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
50%20 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
100%60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
16.7%60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
0%40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
20%40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
0%25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 1
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—450 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—135 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—90 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—60 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—40 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—27 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—18 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—12 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
21.6%a
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
—
NCT02039726 · Phase 3 · registry result, not featured evidence
2.9%30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
—20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
0%20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
2.6%60 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
15.8%30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
—Cohort 1; ≥60 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
—Cohort 2; ≥18 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
—Phase 1 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—40 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
—20 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 1
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—450 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—135 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—90 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—60 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—40 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—27 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—18 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—12 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
Serious AEs
55.1%a
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
69.7%
NCT02039726 · Phase 3 · registry result, not featured evidence
41.2%30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
100%20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
—20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
63.9%60 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
65.8%30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
85.4%Cohort 1; ≥60 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
76.7%Cohort 2; ≥18 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
20%Phase 1 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
40%Phase 2 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
65.6%Phase 2 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
66.7%40 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
0%20 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
50%ALL Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
0%ALL Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
66.7%AML Dose Level 1
NCT01411267 · Phase 1 · registry result, not featured evidence
60%AML Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
40%AML Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
83.3%450 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
100%300 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
75%300 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
52.9%200 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
50%200 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
80%135 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
66.7%90 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
80%60 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
60%40 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
16.7%27 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
50%18 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
33.3%12 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
a
pyrexia 42.6% (placebo 39.6%)
febrile neutropenia 37% (placebo 36.2%)
diarrhoea 36.6% (placebo 35.1%)
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 30 more results
nausea 47.3%
pyrexia 36.5%
anemia 35.7%
NCT02039726 · Phase 3 · registry result, not featured evidence
30 mg/day
platelet count decreased 38.2%
electrocardiogram qt prolonged 35.3%
febrile neutropenia 29.4%
NCT02984995 · Phase 2 · registry result, not featured evidence
20 mg/day
nausea 66.7%
transfusion reaction 66.7%
anemia 33.3%
NCT02984995 · Phase 2 · registry result, not featured evidence
60 mg
nausea 47.2%
pyrexia 38.9%
diarrhea 36.1%
NCT01565668 · Phase 2 · registry result, not featured evidence
30 mg
anemia 47.4%
fatigue 34.2%
febrile neutropenia 31.6%
NCT01565668 · Phase 2 · registry result, not featured evidence
nausea 54.1%
diarrhea 41.4%
fatigue 39.5%
NCT00989261 · Phase 2 · registry result, not featured evidence
nausea 50.6%
vomiting 39.8%
diarrhea 38.1%
NCT00989261 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 80%
blood bilirubin increased 80%
hypocalcemia 80%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
allergic rhinitis 100%
anemia 100%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
hypomagnesemia 65.7%
creatinine decreased 62.9%
hypokalemia 62.9%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
pain 50%
nausea 43.8%
diarrhea 40.6%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
40 mg/day
electrocardiogram qt prolonged 100%
febrile neutropenia 100%
alopecia 66.7%
NCT02834390 · Phase 1 · registry result, not featured evidence
20 mg/day
febrile neutropenia 100%
abdominal pain upper 75%
alopecia 75%
NCT02834390 · Phase 1 · registry result, not featured evidence
platelet count decreased 100%
anemia 50%
ara-c skin rash 50%
NCT01411267 · Phase 1 · registry result, not featured evidence
hypokalemia 100%
anemia 50%
arthralgia 50%
NCT01411267 · Phase 1 · registry result, not featured evidence
anemia 100%
white blood cell decreased 100%
alanine aminotransferase increased 66.7%
NCT01411267 · Phase 1 · registry result, not featured evidence
white blood cell decreased 100%
anemia 80%
febrile neutropenia 60%
NCT01411267 · Phase 1 · registry result, not featured evidence
hypokalemia 90%
hypomagnesemia 80%
platelet count decreased 70%
NCT01411267 · Phase 1 · registry result, not featured evidence
450 mg ID
asthenia 66.7%
diarrhoea 66.7%
disease progression 66.7%
NCT00462761 · Phase 1 · registry result, not featured evidence
300 mg CD
ecg qt prolonged 50%
anaemia 37.5%
cough 37.5%
NCT00462761 · Phase 1 · registry result, not featured evidence
300 mg ID
anaemia 50%
dyspnoea 50%
fatigue 50%
NCT00462761 · Phase 1 · registry result, not featured evidence
200 mg CD
pyrexia 41.2%
vomiting 41.2%
epistaxis 35.3%
NCT00462761 · Phase 1 · registry result, not featured evidence
200 mg ID
nausea 83.3%
chills 50%
diarrhoea 50%
NCT00462761 · Phase 1 · registry result, not featured evidence
135 mg ID
fatigue 60%
febrile neutropenia 60%
nausea 40%
NCT00462761 · Phase 1 · registry result, not featured evidence
90 mg ID
febrile neutropenia 100%
headache 66.7%
nausea 66.7%
NCT00462761 · Phase 1 · registry result, not featured evidence
60 mg ID
disease progression 80%
anaemia 60%
nausea 60%
NCT00462761 · Phase 1 · registry result, not featured evidence
40 mg ID
pyrexia 60%
anaemia 40%
cough 40%
NCT00462761 · Phase 1 · registry result, not featured evidence
27 mg ID
nausea 50%
anaemia 33.3%
fatigue 33.3%
NCT00462761 · Phase 1 · registry result, not featured evidence
18 mg ID
diarrhoea 37.5%
dizziness 37.5%
hypokalaemia 37.5%
NCT00462761 · Phase 1 · registry result, not featured evidence
12 mg ID
abdominal pain 66.7%
cough 66.7%
asthenia 33.3%
NCT00462761 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 37 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Quizartinib

Overall Survival 31.9 vs 15.1 placebo months
time to event · months
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 1 more result
6.23 vs 4.71 Salvage Chemotherapy months @ 195wk*
NCT02039726 · Phase 3 · registry result, not featured evidence · converted to months from 27 weeks as posted
Event-Free Survival 0.03 vs 0.71 placebo months
time to event · months
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 1 more result
1.38 vs 0.85 Salvage Chemotherapy months @ 195wk*
NCT02039726 · Phase 3 · registry result, not featured evidence · converted to months from 6 weeks as posted
Clinical Remission 54.9% (n=268) vs 55.4% (n=271) placebo
responder rate · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 147 Participants as posted
Composite Clinical Remission 71.6% (n=268) vs 64.9% (n=271) placebo
responder rate · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 192 Participants as posted
CR MRD Negative 20.1% (n=268) vs 18.8% (n=271) placebo
event count · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 54 Participants as posted
Composite CR MRD Negative 24.6% (n=268) vs 21.4% (n=271) placebo
event count · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 66 Participants as posted
CRc 56.5% (n=23)30 mg/day
responder rate · % of participants
No placebo or comparator arm
NCT02984995 · Phase 2 · registry result, not featured evidence
show 1 more result
33.3% (n=3)20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
Overall 79.2% (n=24)30 mg/day
responder rate · % of participants
No placebo or comparator arm
NCT02984995 · Phase 2 · registry result, not featured evidence
show 5 more results
66.7% (n=3)20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
40% (n=5) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
100% (n=1) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
77.1% (n=35) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
59.4% (n=32) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
Duration of Complete Response 3.72 months30 mg/day
time to event · months
No placebo or comparator arm
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 16.1 weeks as posted
show 5 more results
NA months20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
2.79 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 12.1 weeks as posted
2.45 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 10.6 weeks as posted
3.78 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 16.4 weeks as posted
1.62 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 7 weeks as posted
Overall Survival 6.3 months @ 156wk60 mg
time to event · months
No placebo or comparator arm
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 27.3 weeks as posted
show 7 more results
7.87 months*30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 34.1 weeks as posted
4.82 months @ 156wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 20.9 weeks as posted
NA months20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
5.86 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 25.4 weeks as posted
5.54 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 24 weeks as posted
4.41 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 19.1 weeks as posted
5.79 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 25.1 weeks as posted
Event-free Survival 3.16 months @ 156wk60 mg
time to event · months
No placebo or comparator arm
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 13.7 weeks as posted
show 3 more results
2.93 months*30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 12.7 weeks as posted
2.77 months @ 156wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 12 weeks as posted
0.02 months*20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 0.1 weeks as posted
LFS 2.1 months @ 156wk60 mg
absolute value · months
No placebo or comparator arm
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 9.1 weeks as posted
show 3 more results
3.72 months*30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 16.1 weeks as posted
0.95 months @ 156wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 4.1 weeks as posted
NA months20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence

+ 20 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Quizartinib's landscape · XY0206's landscape